Literature DB >> 18029124

The ibogaine medical subculture.

Kenneth R Alper1, Howard S Lotsof, Charles D Kaplan.   

Abstract

AIM OF THE STUDY: Ibogaine is a naturally occurring psychoactive indole alkaloid that is used to treat substance-related disorders in a global medical subculture, and is of interest as an ethnopharmacological prototype for experimental investigation and possible rational pharmaceutical development. The subculture is also significant for risks due to the lack of clinical and pharmaceutical standards. This study describes the ibogaine medical subculture and presents quantitative data regarding treatment and the purpose for which individuals have taken ibogaine.
MATERIALS AND METHODS: All identified ibogaine "scenes" (defined as a provider in an associated setting) apart from the Bwiti religion in Africa were studied with intensive interviewing, review of the grey literature including the Internet, and the systematic collection of quantitative data.
RESULTS: Analysis of ethnographic data yielded a typology of ibogaine scenes, "medical model", "lay provider/treatment guide", "activist/self-help", and "religious/spiritual". An estimated 3414 individuals had taken ibogaine as of February 2006, a fourfold increase relative to 5 years earlier, with 68% of the total having taken it for the treatment of a substance-related disorder, and 53% specifically for opioid withdrawal.
CONCLUSIONS: Opioid withdrawal is the most common reason for which individuals took ibogaine. The focus on opioid withdrawal in the ibogaine subculture distinguishes ibogaine from other agents commonly termed "psychedelics", and is consistent with experimental research and case series evidence indicating a significant pharmacologically mediated effect of ibogaine in opioid withdrawal.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029124     DOI: 10.1016/j.jep.2007.08.034

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  23 in total

Review 1.  Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy?

Authors:  Jeanine Ward; Christopher Rosenbaum; Christina Hernon; Christopher R McCurdy; Edward W Boyer
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration.

Authors:  Sebastien Carnicella; Dao-Yao He; Quinn V Yowell; Stanley D Glick; Dorit Ron
Journal:  Addict Biol       Date:  2010-10       Impact factor: 4.280

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 4.  New directions in the treatment of opioid withdrawal.

Authors:  A Benjamin Srivastava; John J Mariani; Frances R Levin
Journal:  Lancet       Date:  2020-06-20       Impact factor: 79.321

5.  Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula.

Authors:  Hugo R Arias; Xiaotao Jin; Dominik Feuerbach; Ryan M Drenan
Journal:  Int J Biochem Cell Biol       Date:  2017-10-16       Impact factor: 5.085

Review 6.  The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).

Authors:  Genís Ona; Juliana Mendes Rocha; José Carlos Bouso; Jaime E C Hallak; Tre Borràs; Maria Teresa Colomina; Rafael G Dos Santos
Journal:  Psychopharmacology (Berl)       Date:  2021-08-18       Impact factor: 4.530

7.  Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Authors:  Laurie Cloutier-Gill; Evan Wood; Trevor Millar; Caroline Ferris; M Eugenia Socias
Journal:  J Psychoactive Drugs       Date:  2016-05-18

8.  N-(Hydroxymethyl)ibogaine.

Authors:  Raoudha Mezghani Jarraya; Amira Bouaziz; Besma Hamdi; Abdelhamid Ben Salah; Mohamed Damak
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2008-08-09

Review 9.  GDNF--a potential target to treat addiction.

Authors:  Sebastien Carnicella; Dorit Ron
Journal:  Pharmacol Ther       Date:  2008-12-24       Impact factor: 12.310

Review 10.  Ibogaine-associated cardiac arrest and death: case report and review of the literature.

Authors:  Jessica A Meisner; Susan R Wilcox; Jeremy B Richards
Journal:  Ther Adv Psychopharmacol       Date:  2016-01-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.